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ABSTRACT
Clostridioides (formally Clostridium) difficile is a medically relevant pathogen pertinent
to infectious disease research. C. difficile is distinctly known for its ability to produce two toxins,
enterotoxin A and cytotoxin B, and the propensity to colonize the mammalian gastrointestinal
tract. It is known that metabolism is tightly correlated with sporulation in endospore producers
such as C. difficile, but an interesting and novel regulatory relationship found by the Ivey lab has
yet to be understood. The relationship explored in this study is observed between the sporulation
factor, SpoIIE, which represses expression of an ABC peptide transporter, app. In this study, two
primary approaches were taken in order to investigate this interaction. The first method involved
directly mutating the gene for SpoIIE in attempt to understand which portion of the gene is
crucial for retaining protein functionality, in this case, the repression of app. The two genes of
interest were readily available on their own individual plasmids, which easily allowed for
mutagenesis experimentation before transformation into E. coli. The plasmid with app was
constructed to include a fluorescent probe, allowing the relative level of repression to parallel the
qualitative measurement of fluorescence. On the SpoIIE containing plasmid, missense point
mutations, done using PCR site-directed mutagenesis, and a large deletion of the SpoIIE protein
transmembrane anchor, done by endonuclease restriction digest, were performed in pursuit of
this investigative method. The secondary approach was to computationally model the SpoIIE
protein structures resultant of the genetic mutations done in vitro. Side-by-side images of the
predicted mutant models produced from the experimentally preferred algorithm were compared
to the wildtype SpoIIE model. The visual analysis of the structures and the comparison of
various algorithms is anticipated to be insightful for not only this project, but future exploration
into SpoIIE as a multifunctional protein within C. difficile.
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AAD

antibiotic associated diarrhea

AA PMC

antibiotic associated pseudomembranous colitis

AS
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Cb
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CDI

C. difficile infection

CFU

colony forming units

DK

aspartic acid à lysine mutant

DQ

aspartic acid à glutamine mutant

GFP

green fluorescent protein

GMQE

global model quality estimate

HA

hospital associated

Kb

kilo-basepairs

Km

kanamycin

LB

Luria Bertani growth media

MDROs

multidrug-resistant organisms

MRSA

methicillin-resistant Staphylococcus Aureus

NMR

nuclear magnetic resonance

Opp

oligopeptide permease protein

PCR

polymerase chain reaction

PDB

protein database

QSQE

quaternary structure quality estimate

RT

room temperature

TM

transmembrane

UA321

University of Arkansas E. coli strain #321 (applies to all)

pUA321

plasmid isolated from University of Arkansas strain #321 (applies to all)

I.

INTRODUCTION
I.1.

Infectious Diseases: an overview

Infectious diseases are often thought of as agents with unknown origins infiltrating the
civilized world, but in actuality, “Infectious Disease” is a term that describes a vast number of
pathogens. The study of infectious diseases involves a complex network of dynamics observed
between the host and parasite and is therefore inherently multidisciplinary (Engering et al.,
2013). This field of research relies on biologists, ranging from molecular and microbial to
ecological and clinical, in order to develop a comprehensive understanding of an infection. In
any clinical context, whether that be pharmaceutical treatment, epidemiological trends, or
prevention medicine, the fundamental three-way interactions between the host, parasite and their
physical environment must be considered.
Infectious disease research is centralized around the relationship between the parasite and
its host. Parasitism is an essential biological relationship and one of the most ubiquitous life
strategies on Earth, as all living organisms are parasitized by at least one other species (Albert et
al., 2002; Balloux & van Dorp, 2017). Parasite is a broad term that can be further divided into
five major types: helminth, fungus, protozoan, bacteria, and viruses (Albert et al., 2002; Janeway
et al., 2001; Kilpatrick & Altizer 2010). Prion is occasionally listed as a sixth category depending
upon the source, as they are infectious proteins but not parasites (Albert et al., 2002; Barreto et
al., 2006). More specifically, a pathogen is a parasite that causes disease to its host, whereas by
comparison few parasites co-exist symbiotically with their hosts in the absence of disease
(Balloux & van Dorp, 2017; Barreto et al., 2006; Casadevall & Pirofski 2000; Kilpatrick &
Altizer 2010). In order to survive, pathogens must colonize a host, subvert both innate and
adaptive immune responses, replicate, and lastly… spread to subsequent hosts (Albert et al.,
2002; Janeway et al., 2001).
1

By definition, disease describes a disorder in structure or function, especially alongside
the production of explicit and identifiable symptoms (Balloux & van Dorp, 2017; Kilpatrick &
Altizer 2010). Often times, disease symptoms presented by an infection aid in the transmission to
the next host (Albert et al., 2002). For example, the common cold, caused by the rhinovirus,
produces excess mucous along with sneezing and coughing; actions that aim to aerosolize viral
particles in hopes of inhalation by another host to exploit (Jacobs et al., 2013). Many diseases
present in the human population are not classified as infectious, but are rather inherited or
congenital, one of the most common being cardiovascular disease (Mc Namara et al., 2019).
Contrastingly, infectious diseases are caused by transmissible and communicable pathogens
(Barreto et al., 2006). This defining quality of being “transmissible” allows for the analysis of
how pathogens are maintained and transmitted within a host population, which often times have
significant clinical implications. Again, emphasizing that understanding these large-scale
infection dynamics is vital and parallel to the analysis of molecular interactions.
Not all infectious diseases arise from the untamed wilderness in spillover events. In fact,
the majority of human pathogens live and thrive in the same environment as us; their hosts
(Dunn et al., 2010). Common human pathogens can be isolated from nearly any public space.
The outdoor environment is home to numerous potential pathogens in the soil such as
Toxoplasmosis gondii and Pseudomonas aeruginosa, while streams can be home to microbes
such as Giardia lamblia and Legionella pneumonia (Gao et al., 2016; Green et al., 1974;
McClung et al., 2017). Raw and unwashed food found in the produce section from a market is an
ideal environment for Escherichia coli or Listeria monocytogenes (Zeng et al., 2014; Zhang et
al., 2018). Industrial facilities, such as a sewage treatment plants, are often the environment for
pathogens such as Enterococcus faecalis and Proteus vulgaris (Cyprowski et al., 2018). Even
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medical settings, such as hospital rooms (places optimistically thought to be sterile) prove to be a
niche environment for opportunistic pathogens such as methicillin-resistant Staphylococcus
Aureus (MRSA) and C. difficile (Hassoun et al., 2017; Walters et al., 1983). Pathogens are
evidently omnipresent, but their pervasiveness is chiefly controlled by host availability and
transmission routes (Kilpatrick & Altizer 2010).
The prevalence of all pathogens is largely dependent on and limited by their mode of
transmission (Antonovics et al., 2017; Barreto et al., 2006; Dunn et al., 2010). There are five
modes of pathogen transmission: direct contact, inhalation, fecal-oral, vector-borne and fomite
(Antonovics et al., 2017). Direct contact infections occur through an open wound or mucous
membrane, such as with sexually transmitted diseases like Chlamydia trachomatis (Phillips
2019). Inhalation transmission is seen in respiratory viruses like coronaviruses, or SARS-CoV-2
(Kucharski et al., 2020). The fecal-oral transmission route is utilized by pathogens like Vibrio
cholerae or Salmonella enterica; the culprits behind many cases of food poisoning (Diard &
Hardt 2017; Rinaldo et al., 2017). Vector-borne pathogens are transmitted to hosts via arthropods
like ticks and mosquitos, some of these being Borrelia burgdorferi, Plasmodium falciparum and
all flaviviruses (Rossati et al., 2016; Schorderet-Weber et al., 2017; Leitner et al., 2015). The
fifth mode, fomite, uniquely requires a secondary mode of transmission, such as ingestion
(Antonovics et al., 2017). The term fomite refers to objects likely to carry microbes that have the
ability to persist in the environment for prolonged periods of time in the absence of a host
(Alberts et al., 2002). Endospore producers commonly exist in their dormant spore-form in the
environment on a fomite, and then germinate into vegetative cells once being either ingested or
inhaled by a susceptible host (Deakin et al., 2012; Saujet et al., 2013). C. difficile is an archetypal
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pathogen that employs this evolutionarily advantageous method of transmission (Paredes-Sabja
et al., 2014).
In the case of microparasites, such as bacteria, the host can additionally be thought of as
the “environment” (Kilpatrick & Altizer 2010). With the exception of fomite transmission, most
parasites cannot survive extensively in the exterior environment without a host. Parasites are
entirely dependent upon their hosts for protection and nutrients in order to subsist (Albert et al.,
2002; Kilpatrick & Altizer 2010). Gastrointestinal pathogens, transmitted through the fecal-oral
route, are ideal examples when considering how the host can double as the environment.
The human body’s temperature, in combination with an anaerobic setting and a radical
drop in pH due to hydrochloric acid found in the stomach, create a unique environment for
invading intestinal pathogens to endure (Fimlaid et al., 2015). Furthermore, as many studies have
published, the human microbiome is a notably complex ecosystem within itself, as the colon is
home to upwards of five-hundred bacterial species alone (Jandhyala et al., 2015; Lozupone et al.,
2012). This intestinal environment proves to be a tricky one for attacking pathogens as they face
high temperatures, little oxygen, an acidic pH, and the normal gut flora as powerful resource
competitors (Lozupone et al., 2012). The successful invaders of the gastrointestinal tract have
shown to be both opportunistic and resilient.
Opportunistic pathogens are defined in medical literature as organisms that “become
pathogenic following a perturbation to their host” (Brown et al., 2012). Nosocomial infections,
ones originating from hospitals, are conventionally and fundamentally understood to be driven
by opportunistic pathogens (Fimlaid et al., 2015). Hospitals are home to the weakest and most
susceptible host population while simultaneously housing some of the most aggressive and
resilient pathogens. Numerous hospital residents are recipients of heavy antibiotics following a
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range of routine procedures (Rupnik et al., 2009). In many cases, these antibiotic therapies
protect patients against subsequent infections, but inadvertently, this makes patients intestinally
available for opportunistic colonization as normal gut flora become deficient (Barreto et al.,
2006; Brown et al., 2012). Due to their unique infection dynamics within a specific niche, an
entire division of infectious disease research is dedicated to nosocomial infections (Alberts et al.,
2002; Casadevall & Pirofski 2000). C. difficile is the ideal model of an opportunistic, nosocomial
pathogen as these intestinal infections almost exclusively originate from healthcare settings
(Deneve et al., 2009; Dodson & Borriello 1996).
Aside from being opportunistic, C. difficile is also considered to be a highly resilient
pathogen because of its ability to produce endospores (Deakin et al., 2012; Fimlaid et al., 2015).
As briefly mentioned, the production of endospores allows for C. difficile to withstand a variety
of harsh environmental factors. Spores can exist on various medical surface fomites as they are
resistant to desiccation and disinfectants (Lawley et al., 2009). These metabolically dormant
spores can then be unintentionally ingested by abundantly available and susceptible hosts
(Paredes-Sabja et al., 2014). Not only do the spores successfully evade death by disinfectants,
they also have the uncanny ability to survive the stomach pH, and then germinate in the intestinal
tract (Fimlaid et al., 2015). Successful colonization of the intestinal tract by C. difficile is
primarily seen in the absence of resource competitors, or the normal gut microbes removed
through antibiotic therapy (Walters et al., 1983).
The aforementioned infection dynamics are multifaceted and highly distinctive to this
system. The transmission route, niche susceptible host population, and evolutionary reproductive
tactics, make C. difficile a fascinating organism in which to study infection at a molecular scale.
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C. difficile is a medically relevant pathogen with unique microbial properties that make it an
interesting model for infectious disease studies.
I.2.

C. difficile: history and facts

C. difficile is a gram positive, anaerobic, endospore producing bacilli that is virtually
endemic to hospitals and their population of vulnerable hosts (Redelings et al., 2007). In the
context of this infectious disease, a vulnerable host is one who has deficient normal intestinal
flora or a weakened immune system (Bartlett & Gerding 2008). Generally, these are
characteristics resultant of both broad-spectrum antibiotics and chemotherapy, two commonly
received medical treatments, which have aided in the creation of a niche population of
susceptible hosts for C. difficile in the medical setting (Murphy et al., 2012; Redelings et al.,
2007). Furthermore, transmission within the hospital patient host population, demonstrates
horizontal and density-dependent transfer between individuals (McDonald 2013). Horizontal
transmission indicates that any individual within the identified host population can become
infected, while density-dependent refers to the statistical increase in incidence seen with an
increase in available hosts (Kilpatrick & Altizer 2010; McDonald 2013).
C. difficile is the reigning cause of nosocomial gastrointestinal diseases and a leading
causative agent for antibiotic associated diarrhea (AAD) (15-25% of all reported cases) in
Western and European countries for nearly five decades (Bouza et al., 2012; Dubberke & Olsen
2012; Freeman et al., 2010). In the United States alone, the C. difficile mortality rate reported an
increase of 5.7 per million in 1999, to a rate of 23.7 per million just five years later in 2004
(Redelings et al., 2007). C. difficile remains a prevalent nosocomial pathogen because of its
ability to evade antimicrobials through endospore production, seen both inside the host and in the
exterior environment (Fimlaid et al., 2015). Despite being anaerobic, C. difficile persists without
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a host in an oxygenic environment by existing as spore fomites (Fimlaid et al., 2015; Pereira et
al., 2013; Underwood et al., 2009). These infectious spores survive surface disinfectants and
germinate into vegetative cells after ingestion (Casadevall & Pirofski 2000; Janeway et al.,
2001). This is representative of the fecal-oral transmission route as discussed above. Within the
host, that same ability to produce spores also contributes to the survival of C. difficile despite the
use of antibiotics aimed at clearing the infection (Walters et al., 1983).
The disease spectrum seen in C. difficile infections is highly variable (Bartlett & Gerding
2008; Deneve et al., 2009). Symptoms range from mild diarrhea and colitis, to severe toxic
megacolon and sepsis (Bartlett & Gerding 2008; Carman et al., 2011). The most severe cases
result in antibiotic-associated pseudomembranous colitis (AA PMC), a symptom observed only
after established colonization in the colon of patients under heavy antibiotic therapy (Lawley et
al., 2009; Walters et al., 1983). PMC often presents with accompanying symptoms such as
intestinal distention, colitis, abdominal pain, and severe diarrhea (Reinke & Messick 1994;
Surawicz & McFarland 1999). If improperly treated, PMC can further progress into toxic
megacolon and present complications such as organ failure and sepsis (Borriello, 1990; Dodson
& Borriello, 1996; Surawicz & McFarland, 1999; Deneve et al., 2009). As seen with most
pathogens, the course of infection produces symptoms or altered “host behavior” that aim to
increase the likelihood of transmission (Antonovics et al., 2017; Casadevall & Pirofski 2000).
The pathogenicity of C. difficile results in heavy diarrhea and spore shedding into the
environment; a host behavior change that propagates the pathogen’s spread (Engering et al.,
2013). Not only does this elucidate how C. difficile dominates as a resilient and opportunistic
nosocomial pathogen, but this emphasizes the importance of preventative measures for health
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care workers (i.e. gloves, handwashing, etc.) in order to thwart successive spreading to additional
patients (Kampf et al., 2009; Lessa et al., 2012; Paredes-Sabja et al., 2014).
Antibiotic resistance is a growing topic of concern, particularly for nosocomial pathogens
such as methicillin-resistant Staphylococcus aureus (MRSA) and C. difficile (Lawley et al., 2009;
Walters et al., 1983). Their overexposure to antimicrobials (environmental disinfectants and broadspectrum antibiotics) has led to their adaptation to withstand such treatments and the ensuing
emergence of highly virulent strains (Deneve et al., 2009; Fawley et al., 2007; Lawley et al., 2009).
Multi-drug resistant organisms (MDROs) no longer respond to traditionally effective medications
which poses a substantial limitation for patient care and treatment (Walters et al., 1983). Since C.
difficile is already an aggressive and invasive pathogen, there are ongoing programs that monitor
the existence and prevalence of specific strains, as well as precautions that are taken by health
professionals to prevent or delay the appearance of hyper-virulent strains (Lessa et al., 2012;
Walters et al., 1983). One being the intentional avoidance of vancomycin (a powerful broadspectrum antibiotic) to treat C. difficile patients in order to preclude the development of
vancomycin-resistant strains (Surawicz & McFarland, 1999; Walters et al., 1983). Not only does
C. difficile exhibit advantageous transmission tactics that make it incredibly successful in
healthcare settings, but its pathogenicity and ability to produce toxins play a major role in overall
virulence (Di Bella et al., 2016; Lessa et al., 2012; Paredes-Sabja et al., 2014).
I.3.

Pathology: metabolism and toxicity

After accidental ingestion by a susceptible host, C. difficile spores resist destruction by
gastric acid and germinate after reaching the small intestines (Lessa et al., 2012; Paredes-Sabja et
al., 2014). Once in its vegetative and metabolically active state, C. difficile colonizes mammalian
intestines in the absence of normal gut flora, typically after long term antibiotic usage (Depestel
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& Aronoff 2013; Lessa et al., 2012). With the lack of resource competitors, C. difficile
proliferates and dominates the intestinal microbial population (Depestel & Aronoff 2013).
Following successful colonization, C. difficile adheres to intestinal epithelial cells and produces
two toxins which heavily influence the course of the infection (Borriello 1990; Borriello et al.,
1990). These toxins play an insidious role during a C. difficile infection and a plethora of studies
have addressed these toxins, their structures, and the devious effect they have on the host
(Depestel & Aronoff 2013; Di Bella et al., 2016; Lessa et al., 2012; Taylor et al., 1981).
The ability to adhere to the intestinal epithelium acts as an accessory virulence factor for
C. difficile as it aids in toxin delivery and penetration (Di Bella et al., 2016; Karjalainen et al.,
1994). The destructive virulence factors underlying a C. difficile infection are two large
exotoxins, toxin A and B, encoded by genes tcdA and tcdB within the chromosomal DNA
pathogenicity locus (paloc) (Di Bella et al., 2016; Lessa et al., 2012). Toxin B was the first to be
discovered and was initially named “cytotoxin” (Taylor et al., 1981). TcdB is a 250-270 kd
cytotoxin that leads to depolymerization of actin and other cytoskeletal components in
mammalian cell lines in vitro, resulting in the demise of cellular structure and function (Di Bella
et al., 2016; Hecht et al., 1988; Ottlinger & Lin 1988). Toxin A is a 308 kb enterotoxin that
tightly binds epithelial cell receptors, leading to fluid secretion, inflammation, and tissue necrosis
(Just et al., 1995; Kelly et al., 1994). Additionally, tcdA & tcdB glycosylate small Rho proteins
using UDP-glucose as the sugar donor and lead to cytoskeleton disorganization (Deneve
2009) Among common strains, toxin production increases as C. difficile enters the stationary
growth phase, whereas hypervirulent strains also interestingly display toxin production during
the exponential phase (Deneve et al., 2009; Freeman et al., 2010).
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Being that C. difficile is an endospore forming bacteria, sporulation is another metabolic
event also influencing the pathogen’s virulence. Sporulation occurs when vegetative growth is no
longer metabolically favored, and both environmental and cellular signals initiate a complex
cascade of activations ultimately leading to the production of spores (Edwards & McBride 2014;
Saujet et al., 2013; Underwood et al., 2009). Epidemic strains of C. difficile, such as ribotypes
001 and 027, even demonstrate an increase in sporulation capacity, reflected in their increased
virulence (Fawley et al., 2007; Freeman et al., 2010). Spore production is controlled through the
activation of sporulation factors which govern transcription factors, and ultimately up-regulation
of the genes responsible for spore formation (Edwards & McBride 2014; Fimlaid et al., 2013;
Paredes-Sabja et al., 2014; Pereira et al., 2013).
The pathogenicity observed in C. difficile is multifaceted as it involves dynamics that
must take into account metabolic processes such as spore formation and toxin production, both
of which are direct links to the organism’s virulence. Metabolism in general is tightly correlated
with the availability of nutrients and resource utilization (Casadevall & Pirofski 2000). As C.
difficile is living in a peptide rich environment, the gastrointestinal tract, it can be inferred that
successful interaction with the intestinal environment and subsequent cellular transport of
peptides is essential for colonization.
I.4.

The relationship between SpoIIE and ABC peptide transporter, app

In previous experiments done by the Ivey lab, screens of genomic libraries were
preformed in order to identify gene products regulating peptide transport in C. difficile. Studying
cellular peptide transport can be insightful for understanding resource utilization and metabolism
in the context of virulent organisms, which is why the preceding project was pursued. The
central method used in these screenings involved the use of a green fluorescence protein (GFP),
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which was fused onto the promoter region of the app (formerly opp) oligopeptide transporter.
This allowed for the relative repression levels to be viewed as relative brightness, as the GFP
gene, under the control of the app promoter, was repressed. Two proteins, MtlF and SpoIIE,
were identified as transcriptional repressors based upon their reduced amount of fluorescence
after screening, and investigating SpoIIE became the focal point of this research project.
SpoIIE is a sporulation factor found in all gram-positive, spore-forming bacteria (Saujet
et al., 2013). It is most aptly characterized in the model organism, B. subtilis, which is analogous
to the C. difficile model discussed in this study. SpoIIE is a multifunctional protein directly
involved in the regulation and timing of spore development through septum formation and
activation of transcription factors (Barak et al., 1996; Carniol et al., 2005). SpoIIE has a TM
domain of 10 helices on the N-terminus, a C-terminus phosphatase domain, and a central domain
with ambiguous function (Arigoni et al., 1999; Carniol et al., 2005). The TM domain allows for
SpoIIE membrane integration and localization, while the cytoplasmic phosphatase domain both
catalyzes the dephosphorylation of anti-sigma factor SpoIIAA and also binds specific
cytoskeletal proteins such as FtsZ and RodZ (Ben-Yehuda & Losick 2002; Lucet et al., 2000).
SpoIIE exists as a dimer, and the dimerization of this protein is believed to play a role in the
regulation and timing of the phosphatase domain activity (Arigoni et al., 2002).
The C-terminus portion of SpoIIE, or the phosphatase domain, has previously been
crystallized and is more thoroughly studied than the remaining domains of SpoIIE as it belongs
to a large family of PP2C serine phosphatases (Arigoni et al., 2002; Barak et al., 1996). In
addition to the phosphatase domain, this cytoplasmic region contains a long alpha-helix which
serves as the dimer interface while also indirectly interacting with the phosphatase domain via a
helical hairpin referred to as the “switch” (Arigoni et al., 2002). The switch rotates upon
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dimerization and activates the adjacent phosphatase region of SpoIIE (Arigoni et al., 2002;
Carniol et al., 2005). Being that only the C-terminus of the B. subtilis SpoIIE protein has been
crystallized, there is still much to be determined about the protein structure and function within
the central and N-terminus domains, especially when directing this study back to the C. difficile
model.
The peptide transporter, app, is an oligopeptide permease protein falling into the broad
classification of an ABC transporter and ATP-binding cassette, which actively transports
substrates such as peptides (Beis 2015; Locher 2016). App consists of five subunits, A, B, C, D
and F, each with a specific role in the recognition, binding and ultimately transport of peptides
(Steglich et al., 2018). Furthermore, each subunit of app has its own corresponding gene within
the app locus (Arigoni et al., 2002). Curiously, the genes are divided and controlled by two
promoters in opposite directions (Figure 1.1.). These promoters were mapped previously in the
Ivey Lab. Studies with GFP fused to the promoter-containing locus revealed that SpoIIE
represses appDF expression. The directness of the connection between SpoIIE expression and
repression of appDF is unknown, and the first step to gathering an understanding of this
regulatory relationship relies on investigating SpoIIE protein structure and function. This

Figure 1.1. App locus Image generated using Adobe Illustrator to edit a VectorNTI
image.
investigation is designed around evaluating mutations within critical domains of SpoIIE in order
to assess the affects they have on function.
12

Within the B. subtilis model, specific SpoIIE mutants have been created that are defective
in one or all functions mentioned (Barak et al., 1996). Mutations targeting the switch exhibit
defective phosphatase activity, while mutations targeting the alpha-helix prevent dimerization
and therefore all subsequent protein function. Similar mutations have been targeted within the C.
difficile SpoIIE protein sequence in order to understand the repression of appDF transcription
discussed above. It is unknown whether the repression is direct, mediated, or whether
phosphatase activity is required for repression to occur. The following project outlines the
experimental design, both in vitro and in silico, and discusses the findings, their implications,
and future research directions.
I.5.

Research aims

In an attempt to understand the regulatory interaction observed between sporulation factor,
SpoIIE, and the ABC peptide transporter, app, specific mutations can be made to SpoIIE in order
to genetically investigate which portion of the gene is crucial for maintaining the regulatory
function it has on appDF. This is an organized, molecular investigation into a specific genetic
relationship that underlies essential pathogen characteristics such as metabolism, sporulation, toxin
production, resource utilization and environment interaction. All of these features play a deliberate
role in how C. difficile interacts with its host and environment and can therefore provide insight
into the nature of this infectious disease.
The following is the central hypothesis: If certain mutations within the gene for SpoIIE
prove to be non-conservative and demonstrate a loss of protein structure and function, then it can
be understood as to which specific portion of SpoIIE is essential for this regulatory interaction
with peptide transporter, app.
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In order to test this hypothesis, two principal research aims were pursued by implementing
molecular genetics methods both in vitro and in silico.
Research Aim 1. The first aim focuses on the genetic investigation of the regulatory
properties of SpoIIE and what parts of the gene encoding SpoIIE, and the protein itself, are
necessary for retaining this function. This aim was pursued using classical molecular biology
techniques to mutate the SpoIIE gene and assess the subsequent protein functionality via
fluorescence assay.
Research Aim 2. For the second aim, bioinformatics software was utilized to supplement
work done in vitro and build computational models of SpoIIE. This research aim is important
because it allows for a visual analysis of SpoIIE protein structure following the mutagenesis
experimentation outlined in the first research aim.
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II.

GENETIC MUTANTS OF SPOIIE AND SCORING OF FUNCTIONALITY
II.1.

Introduction

It is known that sporulation is coupled with metabolic pathways such as toxin production,
but it remains to be understood why when expressed, this sporulation gene SpoIIE, represses the
expression of the gene encoding peptide transporter, appDF, in C. difficile as was found by the
Ivey lab. The correlation between active resource utilization and the metabolic event of sporulation
is crucial to understanding this infectious disease and needs to be examined in the context of overall
pathogenicity of C. difficile. This curious relationship has yet to be investigated and could
elucidate pivotal virulence factors for this destructive and toxic pathogen.
Classical mutagenesis experiments were carried out in order to analyze which portion of
the SpoIIE protein is crucial to retain the regulatory function it has on app expression. The two
genes of interest were originally isolated from C. difficile strain VPI 10463, before transforming
into E. coli (NEB 5-alpha) for subsequent experimentation. Mutants of the SpoIIE gene were
created by either endonuclease restriction digest or by PCR site-directed methods. The two genes
of interest, appDF and SpoIIE, were transformed in E. coli UA321 and presented exclusively on
their own plasmids (pUA321:appDF and pUA626:SpoIIE) in order to examine the changes in
regulation observed between them (Figure 2.1.). Mutation targets within the SpoIIE gene were
selected by using the Qiagen CLC genomics workbench, which also aided in primer design. Two
categorical types of mutations were made: large deletions and missense point mutations. Targets
for genetic mutations were chosen based on their predicted effect on overall SpoIIE protein
assembly, folding, and function. There are three post-translational interactions SpoIIE displays
that served as central experimental targets: integration of monomers, dimerization, and
activation of phosphatase. The restriction digest experiment removed the portion of the gene
coding for the transmembrane anchor; thought to be imperative for integration. This is a stretch
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of approximately 100 hydrophobic amino acids in the truncated version of SpoIIE present on the
pUA626 plasmid. Site-direct mutants contained missense mutations leading to the translation of
incorrect amino acids, potentially essential for dimerization or phosphatase activation. The
missense point mutations were also chosen because of the change in fundamental properties
exhibited by the amino acids. Two mutants were created, D274K and D260Q. DK is shorthand
for a missense mutation changing aspartic acid to lysine at position 274 going from charged,
acidic to charged, basic. DQ is a mutation changing glutamine to aspartic acid at 260, changing it
from uncharged to charged, acidic. It is important to note that these position numbers correlate to
the truncated version of SpoIIE present on the pUA626 plasmid, and not the full SpoIIE found in
databases.

a)

b)

Figure 2.1. Plasmid maps with (a) appDF and(b) SpoIIE genes

As a proxy measurement for expression of the ABC peptide transporter in the presence of
mutant SpoIIE, the plasmid with app has an upstream construct containing the reporter gene,
GFP (green fluorescence protein). When expressed under normal conditions, in the absence of
SpoIIE, this construct brightly fluoresced as appDF was promoted. In the positive control, where
SpoIIE was unmutated, appDF was repressed along with the upstream construct, therefore
showing little to no fluorescence. A discerning range of fluorescence levels were expected to be
observed in this assay.
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II.2.

Materials and Methods
II.2.1.

General culturing methods

Cultures of E. coli were grown in Luria Bertani (LB) growth media in the presence of
carbenicillin (Cb), as the plasmids used carry the bla gene that makes them resistant; allowing
for proper selection. Liquid media was made at 500mL per batch and carbenicillin was added
post sterilization via autoclave, at a concentration of 50 ug/ml, denoted as Cb50. Initial stocks of
cell cultures and plasmids were grown in 25 mL of media at 37°C overnight in a shaking
incubator, with the incubation time ranging from 12-16 hours. Glass flasks with ventilated caps
were used to allowed for proper aeration. These liquid cultures were then used to either create
glycerol stocks to be kept at -80°C, or processed via mini plus™ plasmid DNA extraction system
(Viogene) in order to serve as control stocks of plasmid, kept at -20°C.
Plate culturing was performed on LB Cb plates, which were made in 500mL batches at a
time, resulting in an average of 18 plates. Five-hundred microliters of Cb50 was added to the
liquid media once cooling post autoclave sterilization. Plates were poured near open flame,
allowed to set, and then stored at 4°C until used. Cultures of E. coli were spread onto LB Cb
plates by first pipetting 50-100 µL of cell culture onto the plate surface and then streaking with a
sterile loop, followed by incubation at 37°C overnight (12-16 hours).
II.2.2.

Plasmid DNA extraction

Plasmid DNA extraction was performed as directed by the manufacturer protocol for mini
plus™ plasmid DNA extraction system (Viogene) and the “spin method” was followed. This was
done from either frozen stock of cell culture preserved in glycerol (800µL cell culture in 200µL
80% glycerol) at -20°C or directly from cell culture post-incubation. After plasmid extraction,
samples were evaluated via gel electrophoresis. Specific stocks were set aside as controls, not to
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be mutated. The quality and quantity of plasmid DNA of the control stocks was evaluated with
Qubit™ 2.0 (Invitrogen) spectrophotometry and noted. All plasmid stocks were kept at -20°C
throughout the progression of the project.
II.2.3.

Gel electrophoresis

Gel electrophoresis often served as a qualitative measurement throughout this work for
various purposes. Five grams of 2% agarose gel with 4µL SYBR® Safe DNA Gel Stain
(Invitrogen) was used and ran at 100V for an average of 25 minutes in 1X TAE buffer acquired
from a community lab stock (Tris base 4.844 g/L, acetic acid 1.21 mL/L, EDTA 0.372 g/L).
Additionally, 5 µL of DNA MW 1Kb ladder (VWR) used from an individual stock stored at RT
(10 µL ladder, 20 µL 6X gel loading dye (NEB), 80 µL 1X TAE buffer). A control plasmid
DNA sample was always present in the first well for comparison. 6X loading dye was used by
preference, as loading the wells tended to be more successful with lesser volumes. Images of the
gels were captured using Kodak Electrophoresis Documentation and Analysis System in
combination with ULTRA-LUM, Electronic UV Transilluminator. The images were then
evaluated through an EOS program paired with the Nikon camera on a shared laboratory desktop
computer.
II.2.4.

Polymerase chain reaction (PCR) site-directed mutagenesis

Multiple site-directed mutations were carried out through Polymerase Chain Reaction
(PCR). Quantification via Qubit™ 2.0 (Invitrogen) spectrophotometry was necessary before
beginning, as PCR protocols require known DNA concentrations (ng/µL). PCR site-directed
mutagenesis was preformed via the NEB Q5 protocol, and the primers were designed via Qiagen
CLC genomics workbench. Using the primers shown in Table 2.1., site-directed mutagenesis via
PCR was employed to create missense point mutations within SpoIIE on plasmid pUA626
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extracted from E. coli. Each PCR reaction was performed in 25 µL, comprised of 12.5 µL Q5
hotstart high fidelity 2x mastermix (NEB), 1.25 µL of each F/R primer at a concentration of 10
µM, 1 µL of 1-25 ng of the template DNA, along with nuclease-free water to bring each reaction
to the 25 µL final volume. PCR amplification was done using Thermal cycler (MWG-Biotech)
and the reaction conditions were denaturation at 98°C for 30s, 25 cycles for annealing at 98°C
for 10s, 50-72°C for 10-30s, 72°C for 20-30s/Kb and extension at 72°C for 2 min. These
conditions were taken from the NEB Q5 manufacturer’s protocol.

Table 2. 1. Primers used for PCR site-directed mutagenesis
Mutant
DK

DQ

Sequence (5’à 3’)

Source

F

CTTATCTCAAAAGTTAGAAGGCG

Eurofins

R

GATTTAATGGATTTTGAAATACTT

F

AATAGCAAATGCGATAAGAAGTATTTCAAAATC Eurofins

R

AACTTTCTACTTTCTGAAAAC

Primers

*Primers designed using Qiagen CLC genomics workbench
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II.2.5.

Endonuclease restriction digest mutagenesis

An additional method for mutagenesis was used for the aim of deleting the
transmembrane anchor region of the SpoIIE gene. The endonucleases used for this experiment
were Spe1 and Eco53KI, chosen with the aid of the Qiagen CLC genomics workbench. Two
identical reactions were done in tandem, one to be used for gel electrophoresis evaluation. Ten
microliter reaction volumes were used, consisting of 8µL of plasmid pUA626 with control
SpoIIE, 1µL cutsmart® (NEB) 0.5µL of SPE1, 0.5µL of Eco53KI, incubated in the Thermal
cycler (MWG-Biotech) 37°C for 1 hour. Following incubation, one of the reactions was run on a
gel against control pUA626 with conditions listed above. If the gel showed successful digest,
then the secondary reaction tube was treated with 1µL of VENT DNA polymerase (NEB) and
1µL dNTP from a personal stock (10µL of A, T, C, G and 60µL of DI H2O) and incubated at
72°C for 30 min followed by 3 min at 80°C. The step both inactivated the endonucleases and
created blunt ends on the mutant plasmid. The reaction tube was then cooled to RT before adding
1µL T4 DNA ligase (NEB) and 1µL polynuclear kinase (Promega), left to incubate overnight.

Table 2. 2. Enzymes used in restriction digest mutagenesis
Enzyme
Spe1

Eco53KI

SpoIIE TM

Restriction Site

Source

A'CTAGT (5’à 3’)

NEB

TGATC'A (3’à 5’)
GAG'CTC (5’à 3’)

NEB

CTC'GAG (3’à 5’)
F: CCAGAGCGATTATTTAATAAG
R: CTCGAGCTCGGATCCCCATCG

*Primers designed using Qiagen CLC genomics workbench
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Eurofins

II.2.6.

Mutant plasmid chemical transformation

In both cases of mutagenesis (site-directed and restriction digestion) after confirmation of
mutation success via gel electrophoresis, the new mutant plasmid was transformed into
chemically competent E. coli cells. Initially, E. coli 10-Beta competent cells (NEB) were used
but yielded low transformation efficiency at 1.5 x 106 cfu/µg. Accordingly, transformation
experiments were then carried out with NEB C2987 chemically competent E. coli cells, resulting
in a much higher efficiency. Transformations were performed following the Q5 site-directed
mutagenesis protocol (NEB) for all mutants. After a 1-hour incubation of transformed,
chemically competent E. coli cells at 37°C, two LB Cb plates per transformation were streaked.
Each plate as a minimum (50µL) and maximum (100µL) acceptable amount as stated in the
transformation protocol. The transformed E. coli cells were pipetted onto the plate near open
flame, and then spread either with a sterile loop or L-spreader. These plate cultures were
incubated at 37°C overnight. After receiving the new, highly efficient competent cells, it was
found that 50µL yielded an ideal number of colonies, making that the standard amount used.

II.2.7.

Colony selection and broth cultures

Following the incubation of the transformed chemically competent E. coli (NEB C2987)
cells on LB Cb plates, colonies were selected to grow in liquid media for further processing.
Approximately 6 colonies were picked with a sterile loop and individually inoculated into 4mL
of LB Cb liquid media in glass test tubes. These test tube broth cultures were incubated for 12-16
hours overnight at 37°C in a shaking incubator. Following incubation, 2mL of the cell culture
was processed using mini plus™ plasmid DNA extraction system (Viogene). These highly
concentrated mutant plasmid stocks were either immediately utilized or stored at -20°C for
subsequent experiments.
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II.2.8.

Creation of electrocompetent E. coli stocks

Commercially purchased chemically competent E. coli cells (NEB C2987) were used in
mutant transformations, but the use of electroporation to create electrocompetent E. coli cells
was necessary to observe the regulatory relationship in question. This is because the E. coli strain
(pUA321) containing the plasmid with the app locus (peptide transport gene) is not store-bought,
but rather developed by the Ivey lab. Therefore, it must be made electrocompetent via
electroporation so that transformation of the plasmids containing the SpoIIE mutants (pUA626)
yields a new E. coli UA321 strain where both plasmids are present (pUA321 and pUA626).
E. coli UA321 was grown in liquid culture by inoculating 25mL Km50 LB broth with
20µL of glycerol stock and then incubating for 12-16 hours at 37°C. Post-incubation, 1mL was
used to inoculate 50mL LB broth with 50µL of Km50. This liquid culture was permitted to grow
into late log phase, or until a Klett value of 100-150 was reached (approx. 4 hours). At this point,
the culture was kept on ice along with 50mL centrifuge tubes, 10% glycerol stock, and sterile DI
H2O. After multiple centrifugations (11,000rpm at 10 min) and rebalancing with sterile water,
the pellet was suspended in 0.4mL of 10% glycerol, this then was divided up into approximately
6 tubes of 100µL glycerol stocks to be kept at -80°C until transformation via electroporation.
II.2.9.

Mutant transformation to E. coli UA321 and fluorescence prep

In order to evaluate the regulatory relationship observed between SpoIIE and app, the
plasmids with mutant SpoIIE were then transformed into E. coli strain UA321, which contained
the app locus on its own plasmid, pUA321. This transformation was carried out via
electroporation. The electrocompetent E. coli cells were kept on ice, alongside other materials
such as the cuvettes and cuvette holder. One-hundred microliters of electrocompetent E. coli
UA321 plus 1µL of mutant plasmid pUA626 were shocked using the following settings: 1.5 kV,
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200 ohms resistance, and 25microfarads capacitance, using Bio-Rad Gene Pulser™ and then
allowed to incubate for an hour at 37°C in 1000mL of recovery media.
After transformation, 50-100 µL cell culture was pipetted onto prewarmed Cb/ Km LB
plates and then spread with a sterile L-spreader near open flame. 25 mL of Km25 was added to
the Cb LB plates previously described, by spreading 10µL Km onto the plates’ surface 5 minutes
before the introduction of the transformed electrocompetent E. coli UA321. Both antibiotics are
used in this transformation because the plasmid with the SpoIIE mutant is resistant to Cb, while
the plasmid containing the app locus is resistant to Km; therefore colonies present after
incubation will contain both plasmids, as desired. The Cb/ Km LB plates were incubated at 37°C
for 12-16 hours overnight.
The next day, 4-6 colonies were selected to subculture and spread onto a subsequent Cb/
Km LB plate, and their size was noted. The new plate was sectioned off into six partitions and
each selected colony was spread into a designated section, two of which were used for controls.
The two controls (dim and bright) were streaked from freezer stocks previously cultured
and transformed through methods mentioned above. The “bright” control was E. coli UA321 in
absence of SpoIIE: no repression. While the “dim” control was E. coli UA321 in the presence of
unmutated SpoIIE on pUA626: strong repression. The freezer stocks were thawed on ice and
then a loopful was to be streaked onto the plate. After all picked colonies were streaked, the plate
was to be incubated at 37°C for 12-16 hours before observing fluorescence.
II.2.1.

Evaluation of fluorescence

Fluorescence was detected and recorded by using the Canon EOS Utility on a shared lab
desktop Dell connected to a Cannon Rebel T4 camera. Blue light provided by 420 nm
wavelength LED light strips was used for fluorescence excitatation. The sectioned plate, as
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describe in the section above, was removed from incubation and placed with its lid off inside the
viewing arena within the black box. The relative brightness was to be scored against the two
controls. Note: fluorescence methods were only practiced with, no useable fluorescence data was
collected.
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II.3.

Results

II.3.1. Creation of C. difficile SpoIIE mutants
After mutagenesis, the mutants DK and DQ were first evaluated via gel electrophoresis
before further transformations were carried out. The mutated plasmid DNA was stored at -20°C
with the intention of sending them for sequencing in order to confirm that they were successfully
mutated in the manner intended. The endonuclease restriction digest mutant aimed at deleting the
transmembrane anchor region proved to be trickier than the missense point mutations. The
evaluation of this mutant via gel electrophoresis was expected to have yielded obvious results
with such a large sequence missing. Many tactics were employed to try to get this restriction
digest to work. Initially, new endonucleases were ordered in case the ones used from the freezer
stocks were inactive. Second, the protocol outlined in the methods section was tinkered with
numerous times, extending incubations or increasing various enzyme volumes. Third, specific
PCR primers (instead of the endonucleases) were designed using the Qiagen CLC Genomics
Workbench. These primers have not yet been tested because of the lab closures.
II.3.2. Experimental progress
Unfortunately, this portion of the project came to an abrupt halt and as a result, no
concrete data was gathered for analysis of the mutants. In the early Spring of 2020, the
University of Arkansas labs closed for non-essential research due to the on-going Covid-19
pandemic which impacted many research projects, including this one. In light of the pandemic, a
second research aim, and therefore third chapter, was pursued in order to supplement the loses
exhibited in this section. The additional research aim was geared to be achieved in the absence of
a laboratory and focused on computational modeling of the protein structures resultant of the
genetic mutations outlined in this chapter.
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II.4.

Discussion

As mentioned, the intentions of this research aim were to assess protein function
following mutagenesis experimentation. The presence of GFP on the plasmid containing appDF,
fundamentally provided a qualitative measurement of expression for appDF in the presence of
mutated SpoIIE. The level of repression would parallel to the relative level of fluorescence
produced by the E. coli colonies transformed with the modified plasmids. Having two controls,
the “dim” and “bright” control, would have allowed for the comparison of the brightness
exhibited by the mutants when streaked and grown upon the partitioned plate described. The
experimental design for the creation of the C. difficile SpoIIE mutants required the exercise of
many classical microbiology and molecular biology techniques, but the lack of data collected
proved to be disappointing.
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II.5.

Conclusion

The in vitro goals pursued in this research project ultimately lack conclusive evidence to
either support or reject the stated hypothesis. The absence of results is not due to experimental
failure, but rather external and circumstantial reasons. This leaves room for incoming graduate
researchers to confidently complete this mutagenesis assay, which will be discussed in Chapter
IV: Future Directions.
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III.

COMPUTATIONAL MODELING OF SPOIIE STRUCTURE
III.1.

Introduction

A growing number of biological sciences are beginning to fundamentally incorporate and
rely on in silico techniques to substantiate in vitro results. The structural modeling of proteins is
an example of how computational techniques provide unique visual representations of molecular
interactions otherwise limitedly studied in the lab. Three-dimensional images of proteins can aid
in the visualization of complex interactions. These images show secondary protein structures
such as helices or sheets, and their resulting tertiary arrangement (Bienert et al., 2017; MartíRenom et al., 2000). Being able to conceptualize these structures elucidates the mechanisms
underlying enzymatic events such as active site binding and protein-protein interactions.
Modeling of structurally unknown or “target” proteins is done by taking the DNA
sequence data or the primary amino acid sequence and aligning it with the sequence of a
structurally similar template (Martí-Renom et al., 2000). This predictive technique is known as
homology or comparative modeling. The quality and accuracy of the structures generated
through homology modeling is dependent upon the sequence identity between the target and the
template. Alignments with low E-values signify that the template and target protein are closely
evolutionarily related (Martí-Renom et al., 2000). Protein tertiary structures are more conserved
than DNA sequences, and a sequence identity above 20% is ideal and renders significantly
similar protein structures that share similar properties (Martí-Renom et al., 2000; Chothia &
Lesk 1986). Inaccuracies in homology modeling are derived from initial errors in template
selection and alignment, so the choice of template is a crucial step.
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In this study, SpoIIE from the analogous model organism, Bacillus subtilis is used as the
template, as this protein structure is known. The phosphatase domain (C’ terminus) of SpoIIE
has previously been crystallized and the structure is readily available in online protein databases
(PDB) to use as the template. After the production of the target C. difficile SpoIIE phosphatase
domain, models of the unknown central domain and N’-terminus TM domain were created
through non-template threading, which is a method that produces models based off structural
homologs in the PDB, rather than relying purely on sequence similarity. This created a novel
structure comprised of all three protein domains.
Prior to the creation of this complete SpoIIE model, multiple algorithms were assessed
and compared for their initial sequence alignment and the resulting models. This was done by
comparing sequence identity, model quality estimates, clash values, and then the side-by-side
visualization of the model variants. Additionally, after the webservices were analyzed, preferred
ones were chosen to model the target C. difficile SpoIIE mutants. Qualitative conclusions based
upon the structural models are discussed in this section.

Figure 3.1. Primary sequence: C. difficile SpoIIE, UA001
*Image created using Qiagen CLC Genomic Workbench
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III.2.

Materials and Methods

III.2.1.

Sequence alignment and template selection

The first step in homology modeling is to find a suitable template from which the
predictive model is based. The template was predicted to be that of B. subtilis SpoIIE, as it is
comparatively used in countless studies paralleled to C. difficile. Despite this projection, the
primary sequence, or FASTA file, of the lab’s truncated SpoIIE was BLAST against multiple
databases in order to confirm a reliable template was used for homology modeling. This step was
done in combination with modeling as the web servers used are full pipelines, preforming all
required steps to produce a model. The sequence identities derived from these searches are
reported in Results. As an additional independent search, a BLAST was run against the EMBL
(European Molecular Biology Laboratory) database, which yielded similar top results of B.
subtilis SpoIIE strain 168 with a sequence identity of 27.5% and an E-value of 3.5e-50. Sequence
identities must be above 20% in order to use homology modeling. The sequence coverages are
almost entirely for the phosphatase domain, whose crystal structure exists in the PDB. Across
multiple services, this domain’s coverage was upwards of 95%.
III.2.2.

Modeling programs

Multiple bioinformatics software services, accessed through free online servers, were
used to develop structural models of C. difficile SpoIIE through homology modeling against a B.
subtilis template. Each of the websites used have their own algorithms, which allowed for
comparison of scores and model constraints. The websites used were Swissmodel, Phyre and
Robetta. After the modeling softwares were analyzed for their respective capabilities, the
structural mutants were then modeled and compared.
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III.3.

Results

III.3.1.

Homology modeling

The FASTA sequences of C. difficile SpoIIE (Appendix Figure A 1.) and B. subtilis
(Appendix Figure A 2.) were aligned. The sequence for B. subtilis is notably longer, because as
mentioned in Chapter 2, the C. difficile SpoIIE sequence from pUA626 is truncated and missing
a little over 200 amino acids from the complete TM sequence. The C. difficile SpoIIE FASTA
consists of multiple domains, of which the C’-terminus or phosphatase domain is the most
studied. In order from N’à C’ the sequence shows ~4 TM helices, a linker region, an alphahelix, and the regulatory and catalytic phosphatase domains (PPM). The sequence -LDYD- in the
C. difficile SpoIIE FASTA signifies the beginning of the phosphatase domain. When preforming
homology modeling, the FASTA sequence was cut after -LDYD- at amino acid number 245, in
order to report the highest coverage and confidence level. This begins the phosphatase domain,
which has previously been crystallized and the X-ray crystallization structure data is available in
these databases to use as the template for the C. difficile SpoIIE being studied in this project. The
reported coverages after cutting the FASTA at amino acid 245, were all over 95%, which is ideal
for homology modeling.
Three bioinformatic programs were used: Swissmodel, Robetta, and Phyre. These are all
full pipeline webservices, meaning that they not only find a suitable template, but also execute a
pairwise sequence alignment with the target, and produce the resultant homology model. These
algorithms also report model evaluation values assessing their quality and constraints, which
were considered before continuing on with mutation modeling.
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The homology models from Swissmodel, Robetta and Phyre of the phosphatase domain
appear nearly identical, which is a nice visual validation for algorithm accuracy. These images
are shown side-by-side in Figure 3.2. It is important to note that the model produced by Phyre is
not dimerized like the other two images. Numerically, the models prove to be similar as well,
with identical sequence similarity, coverage, and confidence levels. The homology modeling of
the SpoIIE phosophatase domain is reliable and was preformed with ease due to the presence of
the B. subtilis homolog in the PDB.

(a)

(b)

(c)

Figure 3.2. C. difficile SpoIIE phosphatase domain: Swissmodel (a), Robetta (b), Phyre (c)
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After modeling the phosphatase domain, the N’-terminus or truncated TM region (first
100 amino acids) was also homology modeled through Phyre (Figure 3.3.) The generated image
looks exactly as expected, with four TM helices. Interestingly, the template used for this target
sequence was a thiamine binding protein with 25% sequence similarity. Phyre modeled 72%
(coverage) of the TM region FASTA sequence with 94.3% confidence. Phyre was chosen as the
program for this homology model as the job was completed the fastest, and created the best
visual representation.

Figure 3.3. C. difficile SpoIIE transmembrane
domain: Phyre
After creating the initial homology models, the phosphatase domain was further
evaluated using Phyre, and the analyses are shown in Figure 3.4. Phyre2 and SuSPect are
investigative sister programs that have the ability to assess point mutation effect on structure (a),
the potential for steric clashes (b), as well as provide a Ramachandran analysis (c). The coloring
scheme of the models below show red as indicating the most problematic points.
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The reports generated and shown in Figure 3.4 reflect the missense mutations outlined in
Chapter 2. Image (d) is of amino acid 260, specifically looking at mutant DQ, while image (e)
specifically shows amino acid 274, or mutant DK. These bar graphs show which point mutations
are likely to be the most deleterious at the indicated point in the FASTA sequence. By
comparison, Phyre is predicting the DQ point mutation to be more likely to affect protein
function than the DK mutation.

(a)

(d)

(b)

(c)

(e)

Figure 3.4. C. difficile SpoIIE phosphatase domain analysis: Phyre2/SuSPect
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III.3.2.

Mutant SpoIIE structural models

After the primary homology modeling was done through multiple servers, mutant models
were then created based upon the point mutations outlined in Chapter 2. The mutant models were
created using Phyre, because of the additional capabilities of Phyre2 and SuSPect, as previously
mentioned. Mutants models were made by manually changing the FASTA sequence before
running the program. As shown in Figure 3.5. and 3.6. the structural conformation of the SpoIIE
phosphatase domain does not appear to change because of the point mutations. As an interesting
way to double check these mutants, the residue preference at these specific points was analyzed
and showed high preference towards the original amino acid. This bar graph is reported next to
the corresponding mutant model.
The TM mutant was not modeled because it cannot be evaluated for loss of function in the
same manner as the point mutations. The TM mutation is very different in nature and should
fundamentally be evaluated in vitro.

Figure 3.5. C. difficile SpoIIE DK mutant model: Phyre2 and SuSPect
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Figure 3.6. C. difficile SpoIIE DQ mutant model: Phyre2 and SuSPect
Importantly, Phyre only shows SpoIIE as a monomer and the point mutations being
analyzed are on the alpha-helix. This alpha-helix is known to serve as the dimer interface, so
questions were raised as to whether or not these point mutations could be affecting dimerization.
This is a functional flaw of the Phyre program, as the mutant models appeared to not have
conformational changes existing as a monomer, but could very well show differences after
forming a dimer.
III.3.3. Non-template threading
In addition to homology modeling, the webservice, Robetta, has a higher predictive
capability in the sense that it can construct non-template models through threading and foldrecognition programming. Robetta was able to predict the structure of the full FASTA sequence,
and not just phosphatase domain. Threading programs have the unique ability to produce models
with or without sequence similarity; template-free. These types of alorithms search the PDB for
structural homologs and folding pattern similarities rather than just relying on sequence
similarity.
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This created a novel model of C. difficile SpoIIE, spanning the entire truncated lab
version of SpoIIE. There is no comparative structural protein data on the SpoIIE central linker/
switch domain via NMR or X-ray crystallization, so the algorithm made its modeling predictions
based off the target FASTA sequence and structural homologs in the PDB. This method is
structurally not the most reliable, but the generated model is shown in Figure 3.9. The reported
confidence level is 57%. The TM region is depicted in purple, the linker/ central domain in blue,
and the phosphatase domain spans green through red. The phosphatase domain is recognizably
similar in this model to the other homology models shown in this chapter. It can be assumed that
a large portion of the 57% confidence level is due to the data available on the phosphatase
domain, which accounts for over half of the structural model.
Interestingly, the TM membranes modeled by this program do not show the four TM
helices as one would predict these hydrophobic regions to appear. Robetta shows the truncated
TM SpoIIE gene fragment to possibly be encoding a soluble, dimeric form of SpoIIE. This is
highly speculative, but if this model is correct then the soluble form of SpoIIE could be isolated
and crystallized. This hopeful find for the lab is discussed in Future Directions.

Figure 3.9. C. difficile SpoIIE complete model: Robetta
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III.4.

Discussion

Protein structure determination through experimental methods such as NMR (nuclear
magnetic resonance) or X-ray crystallography is time-consuming and costly, but newer,
progressive techniques have taken main stage as computational modeling further develops.
Knowledge based methods like homology modeling are increasing popular and provide an
efficient alternative to determining protein structures.
The modeling of C. difficile SpoIIE exhibited in this study confidently depicts the
phosphatase domain through homology modeling with a template structure derived from B.
subtilis SpoIIE. Across all webservices used for homology modeling, the confidence level was
above 95%. The TM region was also accurately modeled, portraying four transmembrane
helices, as expected. The SpoIIE gene used in these experiments was known to be the truncated
version, having just four of the ten TM helices. Comparatively, Robetta modeled this same TM
region quite differently, showing a cluster of helices in a formation not observed in highly
hydrophobic domains.
In order to model the central linker domain of C. difficile SpoIIE, a different approach had
to be taken as there is no template data available for homology modeling. The program Robetta
was used to model this region template-free through protein threading. This developed a
complete predicted image of SpoIIE. This model was made by an algorithm that searches the
PDB for folding and structural homologs in order to develop a comparative model for the
portions of the target sequence lacking a homologous template sequence.
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After SpoIIE was modeled through various methods, the point mutations outlined in
Chapter 2 were evaluated by Phyre. According to Phyre, the point mutation denoted as DQ is
likely to have a deleterious effect on protein function. Excitingly, this can be tested for appDF
repression in vitro upon lab reopening by completing the fluorescence assay. Contrastingly, the
DK mutant is not projected to effect function to the same extent. These predictions are an
exciting way to visualize the effects of the PCR site-directed mutagenesis experiments discussed
in Chapter 2. The relative fluorescence levels in vitro may mirror this prediction, where for
example, the lesser effect on function in the DK mutant may still fluoresce at a level similar to
the dim control as this SpoIIE mutant may still functionally repress appDF.
Alternatively, Phyre was unable to predict conformational changes that may occur once
the monomeric form of SpoIIE is dimerized. This disadvantage can be overcome by further
structural investigation by other mutant modeling programs, and is an example of how the
preferred modeling program to use ultimately depends on the purpose and goal of the project.
As shown by modeling the mutations done in vitro, each program used and their
respective algorithms have their advantages and disadvantages. Modeling of protein structure is a
useful method for investigating unknown relationships, such as the repression of appDF by
SpoIIE, as understanding structure is often the first step to understanding function.
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III.5.

Conclusion

The data presented through computational modeling of mutant SpoIIE elucidates the
experimental mutagenesis effect on protein function. The greatest effect on function should be
seen in the DQ mutant, where aspartic acid is translated rather than glutamine. Comparatively,
the DK mutant is projected to have a lesser effect on SpoIIE protein function. The mutation
analysis program that was used in this study produced a spectrum of predictive effects. This has
the potential to mirror the spectrum of relative brightness as would be seen in the fluorescence
assay. It could be that the DK mutant may fluoresce to a level brighter than the DQ mutant, but
dimmer than the “bright” control. The computational analyses done in this project could
effectively complement and substantiate fluorescence data.
It must be noted that the predicted mutational effects simply project whether a mutation
has a statistical probability of interfering with protein function, but do not have the capacity to
forecast which function. This leaves ambiguity as SpoIIE is a multifunctional protein. If the
fluorescence assay results do not match the computational predictions, then this project could
provide insight into SpoIIE function beyond appDF repression or involvement in peptide
transport. Both point mutations were located on the cytoplasmic alpha-helix which is known to
be involved in the timing and regulation of the phosphatase domain activity. This long alpha
helix serves as the dimer interface, so if the DK or DQ mutations happen to interfere with
dimerization, then an entire cascade of sporulation events may be inhibited.
Regardless of the outcome for future experimentation, the protein modeling of C. difficile
SpoIIE has proven to be a useful tool and could aid in furthering the holistic understanding for
the pathogenicity and virulence factors of this infectious disease.
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IV.

FUTURE DIRECTIONS
In light of the results presented from both of the stated research aims, future investigation

into this topic may take three presumable routes. The first is quite simple, in that incoming
graduate researchers could finish the mutagenesis fluorescence assay. The techniques used are
known to be successful by previous students and all materials are abundantly present in the lab.
In addition to evaluating the mutants from this project, future students could also create new
ones. The qualitative fluorescence data to be gathered, may also be interpreted in light of the
structural models created and discussed in this research project. It is expected that application of
these visual structures may bolster future lab projects reliant on in vitro experiments.
Second, it should be investigated as to how these proteins are interacting specifically
within E. coli. SpoIIE is a multifunctional protein, and it should be assumed that it is
dynamically interacting with many other proteins. This scenario must always be considered
when not working in the native cell, here being C. difficile. For instance, it is known that the
SpoIIE C-terminal cytoplasmic domains carry out specific binding to cytoskeletal proteins such
as FtsZ, RodZ, and others (Ben-Yehuda & Losick 2002; Lucet et al., 2000). In the analogous
system Bacillus subtilis, SpoIIE interacts with FtsZ and Rodz to aid in spore septum formation,
but these interactions are far from understood (Arigoni et al., 1999; Ben-Yehuda & Losick 2002;
Lucet et al., 2000). FtsZ is present in E. coli, so it can be inferred that SpoIIE is involved in
multiple regulatory relationships, not just the one with app focused on in this study. The
structural models of the SpoIIE protein presented in this project, could be applied to further
proteomic studies ideally investigating how transformation to competent E. coli affects this novel
relationship between SpoIIE and app, in the presence of other proteins such as FtsZ.
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Lastly, if the model produced by Robetta is correct, then the SpoIIE gene fragment used
experimentally in the Ivey lab may be encoding a soluble form of the SpoIIE protein, which is
normally membrane bound by the hydrophobic N’-terminus transmembrane region. This freely
dispersed, soluble form of SpoIIE could then be isolated, purified, and crystallized. This is an
exciting possible future direction for the lab as the crystal structure for C. difficile SpoIIE is
presently unknown. Ultimately, the work presented in this thesis may contribute to may future
research projects and potential directions for the Ivey lab.
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VI.

APPENDIX

STVLILLTSIVGGATMGASSGVIIGVASILNNMTSAVYMGIYSFSGLISGAFNKINKYFCIL
GYILSWTIIYLYTSGITSNMMQLRDILLGCLIVLVLPERLFNKIEKLIKSNVASNEIVYDYI
MRSKNLTNSRLNSIYKTYDDLADTFDKIREKDKVLDQRDIANVIDMIHNDECKSCSMRR
MCWESRFNHTYTMVYNILEKIEEKGELSLNDIPKNFRKECMKPESIVKISNHYYKMFVL
DYDWSVKFSESRKLIANQIRSISKSIKSLSQDLEGDIMLDIEKEKNIYEQLERYDITVDKVS
YLTKSNSEFEISIEKKTCHDGCMCEDKIVNIISDLVGENMSVRKIGCHCLGGKCKATFVK
SQKYKAVTEVSAMSRDGHILCGDNYTYMEINDGKYMMAISDGMGKGKKAYEESSATI
DILEKMIDAKIKDEIVIDTINNMLLLKSSEEMFSTLDLGILDLKRGCLETIKMGACSTYIKR
EDGEVDLISSSSLPVGILSDVKIDRKNVKVKEGDYVIMVSDGIVDAGRNNNLGDNWLIY
FLKNIETTNPKEISNLILDRALELQALQI
Figure A 1. FASTA Sequence C. difficile SpoIIE, UA001
MEKAERRVNGPMAGQALEKLQSFFNRGTKLVTHHLHSLFFYKGFIYVVIGFLLGRAFIL
SEVLPFALPFFGAMLLIRRDKAFYAVLAVLAGALTISPKHSLLILAALLAFFVFSKVAAFI
TDDRVKALPIVVFFSMAAARAGFVYAQNGVFTTYDYVMAIVEAGLSFILTLIFLQSLPIF
TVKKVKQSLKIEEIICFMILIASVLTGLAGLSYQGMQAEHILARYVVLSFSFIGGASIGC
TVGVVTGLILGLANIGNLYQMSLLAFSGLLGGLLKEGKKAGAAIGLIVGSLLISLYGEGS
AGLMTTLYESLIAVCLFLLTPQSITRKVARYIPGTVEHLQEQQQYARKIRDVTAQKVDQF
SNVFHALSESFATFYQASDEQTDDSEVDLFLSKITEHSCQTCYKKNRCWVQNFDKTYDL
MKQVMLETEEKEYASNRRLKKEFQQYCSKSKQVEELIEDELAHHHAHLTLKKKVQDSR
RLVAEQLLGVSEVMADFSREIKREREQHFLQEEQIIEALQHFGIEIQHVEIYSLEQGNIDIE
MTIPFSGHGESEKIIAPMLSDILEEQILVKAEQHSPHPNGYSHVAFGSTKSYRVSTGAAHA
AKGGGLVSGDSYSMMELGARKYAAAISDGMGNGARAHFESNETIKLLEKILESGIDEKI
AIKTINSILSLRTTDEIYSTLDLSIIDLQDASCKFLKVGSTPSFIKRGDQVMKVQASNLPI
GIINEFDVEVVSEQLKAGDLLIMMSDGIFEGPKHVENHDLWMKRKMKGLKTNDPQEIA
DLLMEEVIRTRSGQIEDDMTVVVVRIDHNTPKWASIPVPAIFQNKQEIS
Figure A 2. FASTA Sequence B. subtilis SpoIIE
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Figure A 3. Plasmid map pUA626 with SpoIIE: close-up

Figure A 4. Depiction of SpoIIE domains
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